Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. Aug 27, 2024; 16(8): 2620-2629
Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2620
Table 1 Patient characteristics, n (%)
Parameter
Without rebleeding group (n = 87)
Rebleeding group (n = 81)
t/χ2
P value
Age (years)52.84 ± 8.1554.15 ± 7.481.0870.279
Gender (M/F)35 (40.23)/52 (59.77)37 (45.68)/44 (54.32)0.3100.577
BMI (kg/m2)23.39 ± 1.3123.65 ± 1.231.2830.201
Smoking history (Yes/No)11 (12.64)/76 (87.36)10 (12.35)/71 (87.65)0.0001.000
Alcohol history (Yes/No)20 (22.99)/67 (77.01)19 (23.46)/62 (76.54)0.0001.000
Hypertension (Yes/No)9 (10.34)/78 (89.66)9 (11.11)/72 (88.89)0.0001.000
Diabetes (Yes/No)7 (8.05)/80 (91.95)6 (7.41)/75 (92.59)0.0001.000
Hyperlipidemia (Yes/No)8 (9.2)/79 (90.8)7 (8.64)/74 (91.36)0.0001.000
Renal failure (Yes/No)8 (9.2)/79 (90.8)16 (19.75)/65 (80.25)3.0050.083
Pneumonia (Yes/No)6 (6.9)/81 (93.1)12 (14.81)/69 (85.19)1.9840.159
Septicemia (Yes/No)14 (16.09)/73 (83.91)14 (17.28)/67 (82.72)0.0001.000
NSAID use (Yes/No)43 (49.43)/44 (50.57)50 (61.73%)/31 (38.27)2.0950.148
Anticoagulant use (Yes/No)29 (33.33)/58 (66.67)37 (45.68)/44 (54.32)2.1880.139
Table 2 Laboratory parameters, n (%)
Parameter
Without rebleeding group (n = 87)
Rebleeding group (n = 81)
t value
P value
Hemoglobin (g/L)113.95 ± 11.44109.14 ± 10.482.8430.005
Platelet count (× 104/microliter)24.48 ± 8.1522.97 ± 6.371.3440.181
INR1.34 ± 0.181.48 ± 0.293.710< 0.001
Albumin (g/dL)3.91 ± 0.593.79 ± 0.671.1680.244
Table 3 Endoscopic findings, n (%)
Parameter
Without rebleeding group (n = 87)
Rebleeding group (n = 81)
t/χ2
P value
Active bleeding (Yes/No)37 (42.53)/50 (57.47)53 (65.43)/28 (34.57)7.9500.005
Average ulcer size (cm)1.19 ± 0.581.8 ± 0.656.348< 0.001
Number of ulcers (≤ 2/> 2)49 (56.32)/38 (43.68)30 (37.04)/51 (62.96)5.5120.019
Ulcer location (gastric/duodenal)35 (40.23)/52 (59.77)38 (46.91)/43 (53.09)0.5150.473
Table 4 Treatment and management, n (%)
Parameter
Without rebleeding group (n = 87)
Rebleeding group (n = 81)
χ2
P value
PPI therapy (Yes/No)85 (97.7)/2 (2.3)77 (95.06)/4 (4.94)0.2550.613
Endoscopic therapy (Yes/No)60 (68.97)/27 (31.03)30 (37.04)/51 (62.96)15.933< 0.001
Blood transfusion (Yes/No)39 (44.83)/48 (55.17)53 (65.43)/28 (34.57)6.3810.012
Table 5 Spearman correlation analysis

r value
R2 value
P value
Rockall score0.7350.541< 0.001
Hemoglobin (g/L)-0.2150.0460.005
INR0.2810.079< 0.001
Average ulcer size (cm)0.4430.197< 0.001
Renal failure (Yes/No)0.1510.0230.051
Active bleeding (Yes/No)0.2290.0530.003
Number of ulcers (≤ 2/>2)-0.1930.0370.012
Endoscopic therapy (Yes/No)-0.320.102< 0.001
Blood transfusion (Yes/No)0.2070.0430.007
Table 6 Receiver operating characteristic analysis

Sensitivities
Specificities
AUC
Youden index
Rockall score0.9140.8160.9330.730
Hemoglobin (g/L)0.5190.7360.6410.255
INR0.4940.8740.6680.368
Average ulcer size (cm)0.8640.5520.7520.416
Active bleeding (Yes/No)0.6540.5750.6150.229
Number of ulcers (≤ 2/>2)0.630.5630.5960.193
Endoscopic therapy (Yes/No)0.630.690.660.32
Blood transfusion (Yes/No)0.6540.5520.6030.206
Table 7 Logistic regression
Factor
Univariate regression
Multivariate regression
OR
95%CI
β
P value
OR
95%CI
β
P value
Rockall score3.8912.729-6.0571.359< 0.0011.1341.106-1.1640.1260
Hemoglobin (g/L)0.960.932-0.988-0.040.0070.9980.994-1.002-0.0020.317
INR11.6473.092-48.7232.455< 0.0011.1420.926-1.4090.1330.214
Average ulcer size (cm)5.0132.826-9.5771.612< 0.0011.1561.069-1.250.1450
Active bleeding (Yes/No)2.5581.378-4.8220.9390.0031.1171.007-1.240.1110.036
Number of ulcers (≤ 2/>2)0.4560.244-0.843-0.7850.0130.910.824-1.006-0.0940.065
Endoscopic therapy (Yes/No)0.2650.138-0.497-1.329< 0.0010.9080.817-1.01-0.0960.075
Blood transfusion (Yes/No)2.331.257-4.3820.8460.0081.0550.955-1.1660.0540.29